Clinical Trials Browser

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

NCT02450656 2018-08-27

M14AFS

Phase 1/2 Unknown

320 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

188 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Phase 1/2 Unknown

50 enrolled

Thoracic

NSCLC

NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Phase NA Unknown

200 enrolled

Thoracic

EGFR Mutation Positive Non-small Cell Lung Cancer

Clinical Trials

DPTA

TRUMP

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

BELLA

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

M14AFS

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Afatinib Plus Nimotuzumb for NSCLC

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis